The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

Diabetes Obes Metab. 2012 Feb;14(2):112-20. doi: 10.1111/j.1463-1326.2011.01483.x. Epub 2011 Nov 22.

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are attributed to a combination of genetic susceptibility and lifestyle factors. Their increasing prevalence necessitates further studies on modifiable causative factors and novel treatment options. The gut microbiota has emerged as an important contributor to the obesity--and T2DM--epidemic proposed to act by increasing energy harvest from the diet. Although obesity is associated with substantial changes in the composition and metabolic function of the gut microbiota, the pathophysiological processes remain only partly understood. In this review we will describe the development of the adult human microbiome and discuss how the composition of the gut microbiota changes in response to modulating factors. The influence of short-chain fatty acids, bile acids, prebiotics, probiotics, antibiotics and microbial transplantation is discussed from studies using animal and human models. Ultimately, we aim to translate these findings into therapeutic pathways for obesity and T2DM in humans.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Bariatric Surgery
  • Bile Acids and Salts / metabolism*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / microbiology*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diet
  • Fatty Acids, Volatile / metabolism*
  • Gastrointestinal Tract / metabolism
  • Gastrointestinal Tract / microbiology*
  • Gastrointestinal Tract / physiopathology
  • Humans
  • Metagenome*
  • Mice
  • Obesity / metabolism
  • Obesity / microbiology*
  • Obesity / physiopathology
  • Prebiotics
  • Probiotics / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Bile Acids and Salts
  • Fatty Acids, Volatile
  • Prebiotics